Previous close | 212.48 |
Open | 212.48 |
Bid | 198.75 |
Ask | 204.10 |
Strike | 820.00 |
Expiry date | 2026-01-16 |
Day's range | 212.48 - 212.48 |
Contract range | N/A |
Volume | |
Open interest | 48 |
GLP-1 pills are the next frontier for the weight-loss market.
Investors can buy LLY stock based on its strong overall financial performance and robust drug pipeline.
NVS' breast cancer drug Kisqali reduces the risk of disease recurrence by 28.5% in a broad population of patients suffering from early breast cancer.